Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.55 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxytoluic Acid SCHEMBL8352264 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL28037743 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25756 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL11527547 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL31174935 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25338040 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL30538825 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL25337502 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL238307 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 | |
| Hydroxytoluic Acid SCHEMBL622892 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4EHPGDHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-4583870-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Mito Biopharma, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | NEW YORK UNIVERSITY (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4558117-A2 | EXTRACT SOLUTION COMPRISING NYMPHAEA COERULEA FLOWER EXTRACT AND NELUMBO NUCIFERA FLOWER EXTRACT, COMPOSITIONS AND METHODS THEREOF | Coty Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025047885-A1 | RESIN COMPOSITION | 三菱ケミカル株式会社 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024020463-A2 | COSMETIC COMPOSITION | COTY INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-4157914-A1 | PROCESSES FOR PRODUCING AROMATIC DIAMINE-INITIATED POLYETHER POLYOLS | Covestro Deutschland AG (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022119854-A1 | COMPOUNDS FOR THE TREATMENT OF SARS | PURDUE RESEARCH FOUNDATION (US) | 2022-06-09 | — | — | WO | disclosed |
| EP-3962479-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213569-A1 | METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY | DCLRE1B, RNASE1, ADAR | ALDH1A1 3389/4885KDM4E 4082/4885HPGD 3531/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | ALDH1A1 2279/4885KDM4E 2931/4885HPGD 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.